Search results for "CETA"

showing 10 items of 1865 documents

Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial.

2017

Purpose To analyze the impact of postmastectomy radiation therapy (PMRT) for patients with T1-T2 tumors and 1 to 3 positive lymph nodes enrolled on the Breast International Group (BIG) 02-98 trial. Methods and Materials The BIG 02-98 trial randomized patients to receive adjuvant anthracycline with or without taxane chemotherapy. Delivery of PMRT was nonrandomized and performed according to institutional preferences. The present analysis was performed on participants with T1-T2 breast cancer and 1 to 3 positive lymph nodes who had undergone mastectomy and axillary nodal dissection. The primary objective of the present study was to examine the effect of PMRT on risk of locoregional recurrence…

0301 basic medicineOncologyCancer Researchmedicine.medical_treatmentDocetaxelMastectomy Segmentallaw.invention0302 clinical medicineRandomized controlled triallawAntineoplastic Combined Chemotherapy ProtocolsAnthracyclinesMastectomyRadiationHazard ratioCarcinoma Ductal BreastMiddle Agedmedicine.anatomical_structureEditorialOncologyDocetaxelChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleMastectomymedicine.drugAdultmedicine.medical_specialtyAntineoplastic AgentsBreast Neoplasms03 medical and health sciencesYoung AdultBreast cancerInternal medicinemedicineConfidence IntervalsHumansRadiology Nuclear Medicine and imagingCyclophosphamideAgedNeoplasm StagingPostoperative Carebusiness.industryCancermedicine.diseaseClinical trialAxilla030104 developmental biologyDoxorubicinAxillaLymph Node ExcisionLymph NodesbusinessInternational journal of radiation oncology, biology, physics
researchProduct

Does chemotherapy improve survival in patients with nodal positive luminal A breast cancer? A retrospective Multicenter Study.

2019

BackgroundIn this study based on the BRENDA data, we investigated the impact of endocrine ± chemotherapy for luminal A, nodal positive breast cancer on recurrence free (RFS) and overall survival (OS). In addition, we analysed if tumor size of luminal A breast cancer influences survival in patients with the same number of positive lymph nodes.MethodsIn this retrospective multi-centre cohort study data of 1376 nodal-positive patients with primary diagnosis of luminal A breast cancer during 2001-2008 were analysed. The results were stratified by therapy and adjusted by age, tumor size and number of affected lymph nodes.ResultsIn our study population, patients had a good to excellent prognosis …

0301 basic medicineOncologyDose-dense chemotherapyAdjuvant Chemotherapymedicine.medical_treatmentCancer Treatment0302 clinical medicineBreast TumorsMedicine and Health SciencesEndocrine TumorsMultidisciplinaryPharmaceuticsQREndocrine TherapyMiddle AgedPrognosisSurvival RateOncologyDocetaxelChemotherapy AdjuvantLymphatic Metastasis030220 oncology & carcinogenesisMedicineFemaleLymphAnatomyResearch Articlemedicine.drugClinical Oncologymedicine.medical_specialtyScienceBreast NeoplasmsDisease-Free SurvivalLymphatic SystemCancer Chemotherapy03 medical and health sciencesBreast cancerDrug TherapyDiagnostic MedicineInternal medicineBreast CancermedicineHumansChemotherapyEndocrine systemSurvival rateAgedRetrospective StudiesChemotherapybusiness.industryBiology and Life SciencesCancers and NeoplasmsRetrospective cohort studymedicine.disease030104 developmental biologyLymph NodesClinical MedicinebusinessPLoS ONE
researchProduct

The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience.

2017

<b><i>Background/Aim:</i></b> Prostate cancer frequently causes bone metastases and skeletal events that impair quality of life (QoL) and survival. The alpha emitter radium-223 is a new drug that improves treatment in men with castration-resistant prostate cancer (CRPC) and bone metastases. Our aim was to evaluate the effectiveness of radium-223. <b><i>Subjects and Methods:</i></b> In this retrospective study we enrolled 48 subjects. Pain reduction, alkaline phosphatase (ALP), time to first symptomatic skeletal event, and QoL were the variables we evaluated. <b><i>Results:</i></b> Radium-223 was well tolerated, with a m…

0301 basic medicineOncologyDrugRadium-223MaleCancer Researchmedicine.medical_specialtymedia_common.quotation_subjectAntineoplastic AgentsBone NeoplasmsDocetaxel03 medical and health sciencesProstate cancer0302 clinical medicineQuality of lifeInternal medicinemedicineHumansmedia_commonAgedRetrospective StudiesAged 80 and overRadioisotopesbusiness.industryBone metastasisRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseProstatic Neoplasms Castration-Resistant030104 developmental biologyOncologyDocetaxelItaly030220 oncology & carcinogenesisQuality of LifeAlkaline phosphatasePrednisoneTaxoidsRadium-223 Bone metastasis Prostate cancer Radiopharmaceuticals Metastatic castration-resistant prostate cancer Quality of Lifebusinessmedicine.drugRadiumOncology
researchProduct

Anti-angiogenic drugs for second-line treatment of NSCLC patients: just new pawns on the chessboard?

2016

Tumor angiogenesis is one of the main pathways targeted to treat cancer. Bevacizumab added survival benefit when combined with platinum-based chemotherapy in NSCLC. Recently, Phase III trials showed survival benefit when anti-angiogenic drugs are added to docetaxel as second-line treatment for NSCLC. These anti-angiogenic agents include nintedanib and ramucirumab, a tyrosine-kinase inhibitor and a monoclonal antibody, respectively, which target receptors involved in angiogenesis. These studies have some similarities and differences. We propose a new algorithm for treatment sequences in performance status 0-1 patients with non-oncogene-addicted NSCLC type adenocarcinoma. Indeed clearer scien…

0301 basic medicineOncologyIndolesLung NeoplasmsAngiogenesisInvestigationalangiogenesis; docetaxel; nintedanib; NSCLC; ramucirumab; Angiogenesis Inhibitors; Antibodies; Monoclonal; Carcinoma; Non-Small-Cell Lung; Chemotherapy; Adjuvant; Humans; Indoles; Lung Neoplasms; Neovascularization; Pathologic; Practice Guidelines as Topic; Protein Kinase Inhibitors; Taxoids; Therapies; Investigational; Pharmacology; Drug Discovery3003 Pharmaceutical Science; Clinical BiochemistryClinical BiochemistryAngiogenesis InhibitorsNSCLCangiogenesischemistry.chemical_compound0302 clinical medicineCarcinoma Non-Small-Cell LungMonoclonalDrug DiscoverynintedanibdocetaxelNon-Small-Cell LungAdjuvantNeovascularization PathologicTherapies InvestigationalAntibodies MonoclonalDocetaxelChemotherapy Adjuvant030220 oncology & carcinogenesisPractice Guidelines as TopicAdenocarcinomaTaxoidsNintedanibAngiogenesis InhibitorHumanmedicine.drugmedicine.medical_specialtyBevacizumabramucirumabProtein Kinase InhibitorAntibodies Monoclonal HumanizedAntibodiesRamucirumab03 medical and health sciencesTaxoidInternal medicinemedicineChemotherapyHumansProtein Kinase InhibitorsNeovascularizationPathologicPharmacologyPerformance statusbusiness.industryDrug Discovery3003 Pharmaceutical ScienceCarcinomaangiogenesiCancermedicine.diseaseLung Neoplasm030104 developmental biologychemistryIndoleTherapiesangiogenesis; docetaxel; nintedanib; NSCLC; ramucirumab; Angiogenesis Inhibitors; Antibodies Monoclonal; Carcinoma Non-Small-Cell Lung; Chemotherapy Adjuvant; Humans; Indoles; Lung Neoplasms; Neovascularization Pathologic; Practice Guidelines as Topic; Protein Kinase Inhibitors; Taxoids; Therapies Investigational; Pharmacology; Drug Discovery3003 Pharmaceutical Science; Clinical BiochemistrybusinessExpert Opinion on Biological Therapy
researchProduct

Efficacy and Safety of the Oral Multikinase Regorafenib in Metastatic Colorectal Cancer.

2017

<b><i>Background/Aim:</i></b> A clinical trial demonstrated that treatment with oral multikinase regorafenib improved overall survival (OS), progression-free survival (PFS), and disease control [García-Alfonso et al.: J Clin Transl Oncol 2016;18:1072-1081; Bertocchi et al.: J Chemother 2017;29:102-105]. In this study, we aimed to evaluate its effectiveness in Italian patients with hormone-refractory metastatic castration-resistant prostate cancer (mCRPC) progressing after chemotherapy with docetaxel plus prednisone. <b><i>Materials and Methods:</i></b> 60 patients were enrolled. OS has been assessed as the primary endpoint while PFS, quality o…

0301 basic medicineOncologyMaleCancer ResearchColorectal cancerPyridinesmedicine.medical_treatmentDocetaxelKaplan-Meier Estimatechemistry.chemical_compound0302 clinical medicineQuality of lifeAntineoplastic Combined Chemotherapy ProtocolsMedicineRegorafenibAged 80 and overMetastatic colorectal cancerGeneral MedicineMiddle AgedProstatic Neoplasms Castration-ResistantTreatment OutcomeOncology030220 oncology & carcinogenesisAdenocarcinomaFemaleTaxoidsColorectal NeoplasmsAdultmedicine.medical_specialtyAntineoplastic AgentsAdenocarcinomaDisease-Free Survival03 medical and health sciencesRegorafenibInternal medicineOverall survivalChemotherapyHumansAgedRetrospective StudiesChemotherapybusiness.industryPhenylurea Compoundsmedicine.diseaseClinical trial030104 developmental biologychemistryQuality of LifePrednisonebusinessOncology
researchProduct

Treatment with abiraterone in metastatic castration-resistant prostate cancer patients progressing after docetaxel: a retrospective study.

2017

The aim of this study was to evaluate abiraterone's efficacy in Italian patients affected with metastatic prostate cancer progressing after treatment with docetaxel. We conducted a retrospective analysis of 60 patients. Prostate-specific antigen (PSA) reduction in serum was the primary endpoint for evaluating the efficacy of abiraterone in combination with prednisone treatment, whereas reduced pain, safety, progression-free survival, response rate, and overall survival (OS) were secondary endpoints. A significant correlation was noticed between PSA response and OS. Further, the Index Bravais-Pearson (r) correlation allowed us to observe a significant negative interdependence between PSA res…

0301 basic medicineOncologyMalemedicine.medical_specialtyCancer ResearchDocetaxelprostatic neoplasm03 medical and health sciencesProstate cancer0302 clinical medicinePrednisoneInternal medicineabirateroneAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansPharmacology (medical)Neoplasm MetastasisSurvival rateAgedRetrospective StudiesPharmacologyAged 80 and overbusiness.industryandrogen antagonistRetrospective cohort studyMiddle AgedProstate-Specific Antigenmedicine.diseasedrug therapyProstate-specific antigenProstatic Neoplasms Castration-Resistant030104 developmental biologyDocetaxelTolerabilitymetastatic castration-resistant prostate cancerOncology030220 oncology & carcinogenesisPrednisoneAndrostenesKallikreinsTaxoidsbusinessmedicine.drugAnti-cancer drugs
researchProduct

Nintedanib in NSCLC: evidence to date and place in therapy

2016

The treatment of advanced non-small cell lung cancer (NSCLC) is currently driven by the detection of targetable oncogenic drivers, i.e. epidermal growth factor receptor, echinoderm microtubule-associated protein-like 4–anaplastic lymphoma kinase, etc. Those patients who are wildtype for known and valuable oncogenes can receive standard chemotherapy as first-line treatment, with the possibility of adding bevacizumab. With regard to second-line treatment, nintedanib can improve the efficacy of docetaxel. Nintedanib is a tyrosine kinase inhibitor targeting three angiogenesis-related transmembrane receptors. The usefulness of nintedanib as an anticancer agent for NSCLC has been proved by both …

0301 basic medicineOncologymedicine.medical_specialtyBevacizumabPDGFRmedicine.drug_classmedicine.medical_treatmentReviewsPharmacologyNSCLClcsh:RC254-282Tyrosine-kinase inhibitorTargeted therapy03 medical and health scienceschemistry.chemical_compoundangiogenesisVEGFR0302 clinical medicineInternal medicinemedicinenintedanibangiogenesis; FGFR; nintedanib; NSCLC; PDGFR; targeted therapy; VEGFR; OncologyEpidermal growth factor receptorChemotherapybiologybusiness.industryFGFRangiogenesilcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenstargeted therapy030104 developmental biologyTolerabilitychemistryDocetaxelOncology030220 oncology & carcinogenesisbiology.proteinNintedanibbusinessmedicine.drug
researchProduct

Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer: Updated results from multicenter, randomized phase …

2017

0301 basic medicineOncologymedicine.medical_specialtybusiness.industryHematologyOxaliplatin03 medical and health sciences030104 developmental biology0302 clinical medicineGastroesophageal cancerOncologyDocetaxelEsophagogastric cancerFluorouracil030220 oncology & carcinogenesisInternal medicinemedicinebusinessmedicine.drugAnnals of Oncology
researchProduct

Optimized Mouse Models for Liver Fibrosis

2017

Fibrosis is the excessive accumulation of extracellular matrix components due to chronic injury, with collagens as predominant structural components. Liver fibrosis can progress to cirrhosis, which is characterized by a severe distortion of the delicate hepatic vascular architecture, the shunting of the blood supply away from hepatocytes and the resultant functional liver failure. Cirrhosis is associated with a highly increased morbidity and mortality and represents the major hard endpoint in clinical studies of chronic liver diseases. Moreover, cirrhosis is a strong cofactor of primary liver cancer. In vivo models are indispensable tools to study the cellular and molecular mechanisms of li…

0301 basic medicinePathologymedicine.medical_specialtyCirrhosisbusiness.industryLiver fibrosismedicine.diseaseVascular architectureExtracellular matrix03 medical and health scienceschemistry.chemical_compound030104 developmental biology0302 clinical medicinechemistryIn vivoFibrosisMedicine030211 gastroenterology & hepatologyThioacetamidebusinessPrimary liver cancer
researchProduct

Paracetamol – An old drug with new mechanisms of action

2020

Paracetamol (acetaminophen) is the most commonly used over-the-counter (OTC) drug in the world. Despite its popularity and use for many years, the safety of its application and its mechanism of action are still unclear. Currently, it is believed that paracetamol is a multidirectional drug and at least several metabolic pathways are involved in its analgesic and antipyretic action. The mechanism of paracetamol action consists in inhibition of cyclooxygenases (COX-1, COX-2, and COX-3) and involvement in the endocannabinoid system and serotonergic pathways. Additionally, paracetamol influences transient receptor potential (TRP) channels and voltage-gated Kv7 potassium channels and inhibits T-t…

0301 basic medicinePharmacologyDrugPhysiologybusiness.industrymedia_common.quotation_subjectdigestive oral and skin physiologyAnalgesicPharmacologySerotonergicEndocannabinoid systemAcetaminophen03 medical and health sciencesTransient receptor potential channel030104 developmental biology0302 clinical medicineMechanism of actionCOX-3030220 oncology & carcinogenesisPhysiology (medical)medicinemedicine.symptombusinessmedia_commonmedicine.drugClinical and Experimental Pharmacology and Physiology
researchProduct